Bipolar disorder (BD) and borderline personality disorder (BPD) are common and burdensome psychiatric illnesses that are difficult to distinguish, primarily because emotion dysregulation is a core feature of both. 1 Normally, emotion regulation involves both 'topdown' and 'bottom-up' processes of control and regulatory feedback that engage the fronto-limbic network (FLN), 2 and it is hypothesized that disturbances in this network produce the vicissitudes of mood and affective lability that characterize BD and BPD, respectively. Within the FLN, it is the dorsolateral, ventrolateral and medial prefrontal cortices (dl-PFC, vl-PFC and m-PFC) along with limbic structures, such as the amygdala (Ag) and hippocampus that have been most commonly implicated in emotion processing and regulation. 2 To determine the differences between BD and BPD in engaging this network, we used functional magnetic resonance imaging and the emotional Stroop task, which requires the inhibition of interference from emotional stimuli while performing a cognitive task. We also investigated whether differential neural responses could explain clinical differences in the phenomenology of the two disorders.
We acquired imaging data from 16 euthymic BD patients, 13 with BPD and 14 healthy controls (HC) (see Supplementary Methods). Participants were diagnosed on the basis of a structured clinical Diagnostic and Statistical Manual of Mental Disorders-IV interview and completed self-report clinical measures. They were matched demographically, and had no differences in trauma history. Further, there was no difference between the two patient groups in the number of psychiatric medications or manic symptoms (see Supplementary Materials Table 1) .
A binary logistic regression was used to predict membership to BD and BPD groups based on four clinical measures that differed significantly between groups: neuroticism, Depression Anxiety and Stress Scale (DASS), The Emotion Amplification and Reduction Scale, and the Difficulty in Emotion Regulation Scale (DERS). The model was significant, w 2 ¼ 27.02, Po0.001, with an overall accuracy of 90%, and DERS was the only significant individual predictor. According to the model, the log of the odds of a participant being in the BPD group was related to greater emotion regulation difficulty.
The key findings from our a priori regions of interest analyses were that, compared with HC, both patient groups displayed a similar pattern of change involving the lateral PFC, with a reduction of neural activity in the left dl-PFC and a concomitant increase in activity in the right vl-PFC, but a divergent pattern of neural activity involving heightened dorsomedial PFC (dm-PFC) activity in BD and diminished Ag activity in BPD (See Figure 1a) . Of note, there were no significant differences in reaction time or response accuracy across the three groups indicating no discernible behavioral confounds.
To investigate whether similar (vl-PFC and dl-PFC) and differential (dm-PFC and Ag) patterns of neural activity predict the DERS total scores (the strongest determinant of group membership), a hierarchical multiple regression analysis was conducted using the DERS total score as the dependent variable and blood oxygenation level dependent signal changes as the independent variables, while controlling for DASS depression scores. The model was significant (F(5, 36) ¼ 5.58, P ¼ 0.001, R 2 ¼ 0.44) and within this, the left dl-PFC and right vl-PFC were significant individual predictors. This means that as emotion regulation difficulties become more pronounced activation in the left dl-PFC decreases (b ¼ À 153.61), and activation in right vl-PFC increases (b ¼ 81.27), (See Figure 1b) .
Findings from our study suggest that the neural substrates of emotion dysregulation in the two patient groups are similar but Purple is used to depict a similar direction of activity in patient groups. Specifically, dl-PFC activation was decreased, whereas vl-PFC activation was increased in both BD and BPD. Green is used to depict activations in the opposing directions in patient groups. Specifically, dm-PFC activation was increased in BD, while Ag activity was decreased in BPD. (b) Correlation of lateral PFC activations with DERS. In all subjects, blood oxygenation level dependent activity in the lateral PFC correlated with DERS Total scores. Increased vl-PFC activity and decreased dl-PFC activity in our patients, indicates greater difficulties in regulating emotion. not identical. Specifically, reduced dl-PFC activity in both patient groups implies that the ability to exert voluntary control on emotional responses is compromised, 3, 4 which is in keeping with previous reports. [4] [5] [6] In addition, increased activity in the vl-PFC, a brain region involved in the evaluation of affective salience and its impact on choice selection and inhibition, 7 suggests that patients require greater inhibition to override interference from affective words to perform the task. Therefore overall, the lateral PFC is pivotal for cognitive modulation of emotion, and in our study neural activity in this region correlated with emotion dysregulation in all subjects (See Figure 1b) . However, we also identified important differences between the patient groups. In particular, increased dm-PFC activity in BD patients perhaps indicates the recruitment of additional effort to achieve adequate top-down regulation. 8 The need for such additional 'cognitive control' is not evident in BPD, possibly because Ag activity is already diminished. This is interesting given the role of the Ag in stimulus-triggered (bottom-up) emotional processes that are able to influence frontal activity via conscious interpretative feedback. 4 In summary, the results of our study suggest that FLN dysfunction underpins both BD and BPD, but at the same time there are key differences. BD patients require additional top-down cognitive processing to regulate emotion, whereas BPD patients have insufficient bottom-up feedback. Therefore, elucidating the FLN changes that occur in these psychiatric disorders is important for understanding the neural basis of mood dysregulation and the future development of targeted psychological therapies.
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